Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Venlafaxine AND Major Depressive Disorder AND Venlafaxine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    46 result(s) found for: Venlafaxine AND Major Depressive Disorder AND Venlafaxine. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2004-003803-19 Sponsor Protocol Number: WXL101497 Start Date*: 2004-11-10
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydroch...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2024-000605-33 Sponsor Protocol Number: VENL-CAZ-3002 Start Date*: 2026-03-17
    Sponsor Name:Viatris Pharmaceutical Japan GK
    Full Title: An open-label, long-term extension, multicenter study to evaluate the safety and efficacy of venlafaxine in Japanese pediatric outpatients with Major Depressive Disorder (MDD) or Persistent Depress...
    Medical condition: Major Depressive Disorder (MDD) or Persistent Depressive Disorder (PDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2006-001529-24 Sponsor Protocol Number: 190-062 Start Date*: 2007-03-06
    Sponsor Name:Sepracor NV in care of Sepracor Inc.
    Full Title: Adults adminstered Venlafaxine and Eszopiclone Response to Treatment (AVERT): A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered with Venlafaxine in Subjects wit...
    Medical condition: Insomnia Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) SE (Completed) GB (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003658-47 Sponsor Protocol Number: F02207 GE 3 03 Start Date*: 2006-11-21
    Sponsor Name:Pierre Fabre Médicament - IRPF
    Full Title: Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2024-000604-29 Sponsor Protocol Number: VENL-CAZ-3001 Start Date*: 2026-03-17
    Sponsor Name:Viatris Pharmaceutical Japan GK
    Full Title: A placebo-controlled, randomized, double-blind, multicenter study to evaluate the efficacy and safety of venlafaxine in Japanese pediatric outpatients with Major Depressive Disorder (MDD) or Persis...
    Medical condition: Major Depressive Disorder (MDD) or Persistent Depressive Disorder (PDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2005-001217-17 Sponsor Protocol Number: Max-Planck-Institute of Psychiatry Start Date*: 2005-09-12
    Sponsor Name:Max-Planck-Institute of Psychiatry
    Full Title: Comparison of venlafaxine augmentation with lamotrigine, quetiapine, or placebo in treatment resistant depression
    Medical condition: Treatment resistant depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000908-91 Sponsor Protocol Number: D1443L00044 Start Date*: 2008-10-16
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, 6-week, multicentre, open-label, rater-blinded parallelgroup study comparing Quetiapine extended release monotherapy and augmentation with Lithium augmentation in patients with Treatm...
    Medical condition: Treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) AT (Completed) HU (Completed) DK (Prematurely Ended) BE (Completed) GB (Completed) IT (Completed) PT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-006800-34 Sponsor Protocol Number: RONIN Start Date*: 2022-03-31
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: The Role of Negr1 In modulating Neuroplasticity in major depression
    Medical condition: patients with major depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000562-13 Sponsor Protocol Number: 3151A1-309-EU Start Date*: 2004-07-26
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY OF DVS-233 SR AND VENLAFAXINE ER IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
    Medical condition: Major depressive disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001639-19 Sponsor Protocol Number: 15-29900A Start Date*: 2015-06-17
    Sponsor Name:Národní ústav duševního zdraví
    Full Title: The efficacy of transcranial direct current stimulation (tDCS) in the treatment of depression and brain functional changes compared to venlafaxine.
    Medical condition: Depressive disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-007025-51 Sponsor Protocol Number: 12279A Start Date*: 2008-10-28
    Sponsor Name:H. Lundbeck A/S
    Full Title: A randomised, double-blind, parallel-group, placebo-controlled and active-referenced study evaluating the efficacy and safety of three fixed dose regimens of Lu AA34893 in the treatment of Major De...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) FR (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003401-87 Sponsor Protocol Number: SND103285 Start Date*: 2006-02-15
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BE (Completed) FR (Completed) EE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005878-37 Sponsor Protocol Number: 039(C)SC11063 Start Date*: 2012-06-05
    Sponsor Name:ANGELINI
    Full Title: A randomized, double-blind study comparing the efficacy and safety of trazodone OAD and venlafaxine XR in the treatment of patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012375 Depressed mood disorders and disturbances HLGT
    14.1 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    14.1 10037175 - Psychiatric disorders 10012401 Depressive disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) AT (Completed) CZ (Completed) ES (Completed) SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-019556-44 Sponsor Protocol Number: CL3-20098-073 Start Date*: 2010-09-03
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder. A 3-week, randomised, double then single-blind, controlled, parallel gr...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) DE (Completed) ES (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001515-29 Sponsor Protocol Number: 11492A Start Date*: 2006-07-10
    Sponsor Name:H. Lundbeck A/S
    Full Title: Double-blind, randomised, placebo-controlled study comparing the efficacy and safety of two fixed dosages of a novel antidepressant compound to that of placebo in patients with Major Depressive Dis...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) ES (Completed) AT (Completed) SK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004588-19 Sponsor Protocol Number: ESKETINTRD3005 Start Date*: 2015-08-04
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Tre...
    Medical condition: Treatment-resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) ES (Completed) GB (Completed) LT (Completed) FI (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005179-18 Sponsor Protocol Number: RGH-MD-75 Start Date*: 2012-03-12
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A Double-blind, Placebo-controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy In Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10025463 Major depressive disorder, single episode LLT
    14.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008280-96 Sponsor Protocol Number: EMC Start Date*: 2009-08-10
    Sponsor Name:Department of Psychiatry and Psychotherapy, University of Mainz
    Full Title: Randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder – the EMC trial.
    Medical condition: Major Depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025454 Major depressive disorder, recurrent episode LLT
    14.1 10037175 - Psychiatric disorders 10053708 Major depressive disorder with melancholic features LLT
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    14.1 10037175 - Psychiatric disorders 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004584-20 Sponsor Protocol Number: ESKETINTRD3001 Start Date*: 2015-09-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subj...
    Medical condition: Treatment-resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) SK (Completed) HU (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003251-37 Sponsor Protocol Number: ACP-103-054 Start Date*: 2019-06-11
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate R...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 19 03:00:39 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA